Earnings summaries and quarterly performance for Arcus Biosciences.
Executive leadership at Arcus Biosciences.
Board of directors at Arcus Biosciences.
AP
Andrew Perlman
Detailed
Director
AR
Antoni Ribas
Detailed
Director
DL
David Lacey
Detailed
Director
DB
Dietmar Berger
Detailed
Director
JM
Johanna Mercier
Detailed
Director
KF
Kathryn Falberg
Detailed
Director
LH
Linda Higgins
Detailed
Director
NL
Nicole Lambert
Detailed
Director
PM
Patrick Machado
Detailed
Director
YK
Yasunori Kaneko
Detailed
Lead Independent Director
Research analysts who have asked questions during Arcus Biosciences earnings calls.
Daina Graybosch
Leerink Partners
4 questions for RCUS
Also covers: AFMD, BNTX, CGEN +6 more
YN
Yigal Nochomovitz
Citigroup Inc.
4 questions for RCUS
Also covers: ALDX, APLS, ARCT +22 more
Jonathan Miller
Evercore ISI
3 questions for RCUS
Also covers: APLS, ARVN, ATRA +8 more
LW
Li Wang Watsek
Cantor Fitzgerald
3 questions for RCUS
Also covers: AFMD, ALXO, ARVN +7 more
PL
Peter Lawson
Barclays PLC
3 questions for RCUS
Also covers: ADAP, ARVN, BPMC +15 more
Asthika Goonewardene
Truist Securities
2 questions for RCUS
Also covers: ALLO, AUTL, BNTX +9 more
Eva Fortea-Verdejo
Wells Fargo Securities
2 questions for RCUS
Also covers: EXEL, KNSA, KYMR
Jason Zemansky
Bank of America
2 questions for RCUS
Also covers: ABOS, BBIO, CYTK +5 more
Salveen Richter
Goldman Sachs
2 questions for RCUS
Also covers: ACAD, AGIO, ALLO +20 more
Emily Bodnar
H.C. Wainwright & Co.
1 question for RCUS
Also covers: AGEN, AGIO, ATOS +6 more
Karina Rabayeva
Truist Securities
1 question for RCUS
Also covers: AUTL, CGEN, MRSN +1 more
KP
Kaveri Pohlman
BTIG, LLC
1 question for RCUS
Also covers: MDGL, MGNX, NUVB +3 more
Terence Flynn
Morgan Stanley
1 question for RCUS
Also covers: ABBV, AMGN, ARVN +17 more
UR
Umer Raffat
Evercore ISI
1 question for RCUS
Also covers: ALKS, AMGN, BHC +15 more
Recent press releases and 8-K filings for RCUS.
Arcus Biosciences Provides Pipeline and Financial Update at J.P. Morgan Healthcare Conference
RCUS
New Projects/Investments
Guidance Update
- Arcus Biosciences has a cash position of $1 billion, providing a runway into the second half of 2028, which covers initial phase three readouts and proof of concept for early immunology programs.
- The company's lead oncology program, casdatifan, a wholly-owned HIF-2α inhibitor, targets a $5 billion market opportunity in kidney cancer, with its fast-to-market PEAK-1 study aiming for enrollment completion by the end of 2026 and a front-line phase three study planned to commence by the end of 2026.
- Another significant oncology program, quemliclustat, a CD73 inhibitor for pancreatic cancer, has completed enrollment for its PRISM-1 registrational trial, with readout expected in the first half of 2027, representing a $4 billion-plus commercial opportunity.
- Arcus is expanding into immunology with an MRGPRX2 antagonist and a selective TNF receptor 1 inhibitor, both expected to enter the clinic by the end of 2026 or early 2027, with potential proof of concept for the MRGPRX2 antagonist by the end of 2026.
- The discontinuation of the TIGIT program (STAR-221) due to lack of benefit has extended the company's cash runway, enabling further investment in its core wholly-owned programs.
Jan 14, 2026, 11:00 PM
Arcus Biosciences provides update at J.P. Morgan Healthcare Conference 2026
RCUS
New Projects/Investments
Guidance Update
- Arcus Biosciences reported approximately $1 billion in cash and investments as of September 30, 2025, adjusted for November 2025 financing, providing a funding runway until at least 2H 2028.
- The company has two Phase 3 oncology programs: Casdatifan, a wholly-owned HIF-2a inhibitor, with a new Phase 3 trial (PEAK-1) in the 1L setting targeted for YE 2026. Clinical data for casdatifan showed a median PFS of 12.2 months in ARC-20 (Phase 1b/2). Quemliclustat, a small molecule CD73 inhibitor, is in Phase 3 for 1L pancreatic cancer (PRISM-1) with enrollment completed and a readout expected in 1H 2027.
- Arcus plans for its first immunology molecules to enter the clinic in 2026, including an MRGPRX2 antagonist (expected in clinic in the next 6-9 months) and a TNF inhibitor (expected in clinic in late 2026 / early 2027).
- Key near-term milestones include casdatifan monotherapy data at a medical conference in February 2026, casdatifan + cabo PFS data in the next 6-9 months, and initiating the first Phase 3 study for casdatifan in 1L RCC in the next 9-12 months.
Jan 14, 2026, 11:00 PM
Arcus Biosciences provides pipeline and financial update at JPMorgan Healthcare Conference
RCUS
Guidance Update
New Projects/Investments
- Arcus Biosciences reported a strong financial position with $1 billion in cash, extending its runway into the second half of 2028, which covers key Phase 3 readouts and early immunology program proof-of-concepts.
- The company is advancing its wholly-owned HIF-2α inhibitor, casdatifan, for kidney cancer, targeting a $5 billion market opportunity with a fast-to-market Phase 3 study (PEAK ONE) expected to enroll by year-end 2026 and a front-line Phase 3 study planned to start by year-end 2026.
- Its Phase 3 oncology study, PRISM-1, for pancreatic cancer with quemliclustat, fully enrolled in September and anticipates readout in the first half of 2027, representing a $4 billion-plus commercial opportunity.
- Arcus is expanding its pipeline into immunology with two new programs, an MRGPRX2 antagonist and a selective TNF receptor 1 inhibitor, both expected to enter the clinic by early 2027, with initial proof of concept for the MRGPRX2 antagonist by early 2027.
- The discontinuation of the anti-TIGIT Phase 3 program (STAR-221) in GI cancer, due to lack of benefit, extended the company's cash runway.
Jan 14, 2026, 11:00 PM
Arcus Biosciences Provides Strategic Update on Oncology and Immunology Pipeline at JPMorgan Healthcare Conference
RCUS
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- Arcus Biosciences is well capitalized with $1 billion in cash, providing a runway into the second half of 2028, which covers initial Phase III readouts and proof of concept for early immunology programs.
- The company's highest value program, casdatifan (HIF-2α inhibitor), is wholly owned and targets a $5 billion market opportunity in kidney cancer, with a fast-to-market Phase III study (PEAK-1) expected to enroll by the end of 2026 and a front-line Phase III study planned to start by the end of 2026.
- Another significant oncology program, quemliclustat (CD73 inhibitor) for pancreatic cancer, has its registrational trial (PRISM-1) fully enrolled as of September, with readout expected in the first half of 2027, representing a $4 billion+ commercial opportunity.
- Arcus is expanding into immunology with two new small molecule programs, an MRGPRX2 antagonist and a selective TNF receptor 1 inhibitor, both expected to enter the clinic by the end of 2026 or early 2027, targeting multi-billion dollar markets.
- The recent discontinuation of the STAR-221 TIGIT program in GI cancer, following an interim analysis showing no benefit, has extended the company's cash runway.
Jan 14, 2026, 11:00 PM
Arcus Biosciences Outlines 2026 Plans and Financial Outlook
RCUS
New Projects/Investments
Guidance Update
- Arcus Biosciences' highest priorities for 2026 include the rapid enrollment of its PEAK-1 Phase 3 study evaluating casdatifan in IO-experienced ccRCC patients and the initiation of a first-line Phase 3 study for casdatifan.
- The company plans at least three data presentations for casdatifan in 2026, including updated data from the Phase 1/1b ARC-20 study in February, updated data for casdatifan plus cabozantinib mid-year, and data from multiple ARC-20 cohorts in the second half of the year.
- Arcus expects its first development candidate for inflammatory and autoimmune diseases, an oral MRGPRX2 antagonist, to enter clinical development in 2026.
- With approximately $1 billion of cash and investments, Arcus anticipates being able to fund its planned operations until at least the second half of 2028.
Jan 7, 2026, 9:05 PM
Arcus Biosciences Discontinues Phase 3 STAR-221 Study and Shifts R&D Focus
RCUS
New Projects/Investments
Guidance Update
- Arcus Biosciences has discontinued its Phase 3 STAR-221 study, conducted in partnership with Gilead Sciences, Inc., due to futility based on an interim analysis of overall survival in upper gastrointestinal cancers.
- The company will now concentrate its R&D investment and resources on casdatifan, a potential best-in-class HIF-2a inhibitor, and its emerging small molecule inflammation and immunology (I&I) programs.
- Multiple data readouts for casdatifan are anticipated in 2026, alongside the expected entry of a small molecule targeting MRGPRX2 into the clinic in the same year as part of its I&I portfolio.
- Arcus expects to be able to fund its planned operations until at least the second half of 2028, supported by approximately $1 billion in cash and investments.
Dec 12, 2025, 1:30 PM
Arcus Highlights Casdatifan as Key Value Driver and Provides Pipeline Updates
RCUS
New Projects/Investments
Guidance Update
- Casdatifan, Arcus's HIF-2 inhibitor, is positioned as the biggest value driver, with 100% ownership and clinical data showing PFS over 12 months in late-line settings, significantly outperforming Merck's belzutifan (5.6 months).
- The company has three programs in Phase III, including casdatifan, an anti-TIGIT program, and a CD73 inhibitor.
- The anti-TIGIT program (STAR-221) in upper GI cancers, fully enrolled in June 2024, is expected to read out in 2026, with Phase II data indicating overall survival greater than two years compared to 12-13 months for standard of care.
- Arcus maintains a strong financial position with over $1 billion in cash, sufficient to fund initial Phase III readouts for all programs.
- A decision on the optimal casdatifan combination for a frontline Phase III study is anticipated in the second half of next year (2026), following ongoing "bake-off" studies.
Dec 3, 2025, 3:30 PM
Arcus Provides Updates on Casdatifan, Anti-TIGIT, and Pipeline Programs
RCUS
New Projects/Investments
Guidance Update
- Arcus's lead asset, Casdatifan (CAS), a HIF-2 inhibitor, is positioned as a major value driver due to its 100% ownership and demonstrated superior clinical profile compared to Merck's Belzutifan, with a PFS of over 12 months versus 5.6 months in late-line settings.
- The company is advancing CAS into two Phase III studies for clear cell RCC, with the CAS+CABO combination study aiming to complete enrollment by the end of 2026 , and a decision on the best frontline combination for a Phase III study expected by the second half of 2026.
- Arcus's anti-TIGIT program, Domvanalimab, has its first Phase III study (STAR-221) in upper GI cancers, which was fully enrolled in June 2024 and is expected to read out in 2026. This program features an Fc silent configuration, believed to offer a better safety profile.
- The company also fully enrolled its Phase III study (PRISM1) for its CD73 inhibitor, Quemliclustat, in September 2025, ahead of schedule. Arcus maintains a strong financial position with over $1 billion in cash, covering initial Phase III readouts for all programs.
Dec 3, 2025, 3:30 PM
Arcus Biosciences Highlights Key Pipeline Assets and 2026 Milestones
RCUS
New Projects/Investments
Guidance Update
- Arcus Biosciences' primary focus is casdatifan, a HIF-2 inhibitor, which has shown promising early data compared to Belzutifan, with more data expected in 2026 to inform its Phase III strategy.
- The Phase III STAR-221 study for Domvanalimab (anti-TIGIT), which showed differentiated overall survival data in earlier studies, is anticipated to read out in 2026.
- The Phase III study for Quemli (CD73 inhibitor) was fully enrolled in September, with a readout expected based on the typical overall survival of the control arm.
- Arcus Biosciences has over $1 billion in capital to execute on its pipeline programs.
- Enrollment for the Volrustomig (bispecific) combo study was paused due to adverse events, with ongoing assessment of current patients.
Dec 2, 2025, 9:40 PM
Arcus Provides Updates on Key Clinical Programs and Strategic Focus
RCUS
New Projects/Investments
Guidance Update
- Casdatifan (HIF-2 inhibitor) is a primary focus, with significant data expected in 2026 to define its Phase 3 strategy in the second half of the year, showing superior data compared to belzutifan.
- The anti-TIGIT program (DAM) has its Phase 3 STAR-221 study (1,050 patients) expected to read out in 2026, having been fully enrolled in June 2024. Additionally, the STAR-121 study (1,000 patients) will be fully enrolled by the end of 2025.
- Arcus anticipates presenting more mature data for its casdatifan plus CABL combination next year, covering the full 44-patient dataset, which previously demonstrated a 40%+ response rate.
- The company reported having $1 billion+ to execute its programs, and its CD73 inhibitor (Quemly) Phase 3 study was fully enrolled in September.
- Enrollment for the Volroo combo was paused due to early AEs resembling CTLA-4 AEs, and the company is evaluating potential protocol amendments.
Dec 2, 2025, 9:40 PM
Quarterly earnings call transcripts for Arcus Biosciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more